WallStSmart

Enbridge Inc (ENB)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1% more annual revenue ($65.77B vs $65.19B). MRK leads profitability with a 13.6% profit margin vs 11.5%. MRK appears more attractively valued with a PEG of 5.28. ENB earns a higher WallStSmart Score of 63/100 (C+).

ENB

Buy

63

out of 100

Grade: C+

Growth: 7.3Profit: 6.5Value: 4.7Quality: 4.5
Piotroski: 3/9Altman Z: 0.61

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 3.3Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENBUndervalued (+4.6%)

Margin of Safety

+4.6%

Fair Value

$54.02

Current Price

$53.59

$0.43 discount

UndervaluedFair: $54.02Overvalued
MRKOvervalued (-14.9%)

Margin of Safety

-14.9%

Fair Value

$97.76

Current Price

$111.38

$13.62 premium

UndervaluedFair: $97.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENB4 strengths · Avg: 9.3/10
EPS GrowthGrowth
294.9%10/10

Earnings expanding 294.9% YoY

Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Market CapQuality
$116.95B9/10

Large-cap with strong market position

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$277.36B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

ENB4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
5.732/10

Expensive relative to growth rate

Free Cash FlowQuality
$-97.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.612/10

Distress zone — elevated risk

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
5.282/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ENB

The strongest argument for ENB centers on EPS Growth, Debt/Equity, Market Cap.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : ENB

The primary concerns for ENB are Piotroski F-Score, PEG Ratio, Free Cash Flow.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

ENB carries more volatility with a beta of 0.79 — expect wider price swings.

ENB is growing revenue faster at 5.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor OIL & GAS MIDSTREAM industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ENB scores higher overall (63/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Enbridge Inc

ENERGY · OIL & GAS MIDSTREAM · USA

Enbridge Inc. is an energy infrastructure company. The company is headquartered in Calgary, Canada.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?